Comparison of Hemodialysis Techniques in the Removal of Uremic Toxins in Chronic Renal Failure

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying different methods of hemodialysis, a treatment for patients with chronic kidney failure, to see which one is better at removing harmful substances from the blood. The focus is on a new filter called Theranova 400™, which is being compared to other established techniques, including high-flow hemodialysis and hemodiafiltration. The goal is to find a method that may work better for patients who are more vulnerable and not seeing improvements with current treatments.

To participate in this study, you need to be at least 18 years old and have been on hemodialysis for at least six months. You must also have specific health conditions, such as limited urine production and a regular dialysis schedule. If you join the trial, you can expect to receive treatment using one of the dialysis methods for about 12 months while your health is monitored. It's important to note that certain health issues, like active bleeding or uncontrolled diabetes, would prevent you from being eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Chronic hemodialytic treatment (on dialysis for at least 6 months), hemodialytic treatment with MCO filter (Theranova) or HF filter, OL- HDF or HFR with HFR filter17.
• • Continuous use of the same filter for at least 12 months.
• • Diuresis \< 200 ml/day.
• • Trisweekly hemodialysis treatment.
• • Session duration ≥ 210 minutes.
• • Availability of clinical data collected during the follow-up that took place at the O.U. of Nephrology, Dialysis and Transplantation - La Manna
• Exclusion Criteria:
• • Intradialytic hypotension
• • Need for dialysis without heparin
• • Active bleeding
• • Active hematologic diseases
• • Thrombocytopenia
• • Chronic hepatopathies
• • Active systemic inflammatory diseases
• • Uncontrolled diabetes mellitus
• • Temporary vascular access
• • Recurrent vascular access infections